ABHD14B

Across TCGA pan-cancer cohorts, ABHD14B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ABHD14B data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ABHD14B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABHD14B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, ESCA, and KICH are the cancer types where ABHD14B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.113	0.578	.001	24	view →
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	DFS	Median	All	1.000	0.625	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ABHD14B–BRCA (OS)

Open the BRCA breakdown →